JP2016528180A5 - - Google Patents

Download PDF

Info

Publication number
JP2016528180A5
JP2016528180A5 JP2016519629A JP2016519629A JP2016528180A5 JP 2016528180 A5 JP2016528180 A5 JP 2016528180A5 JP 2016519629 A JP2016519629 A JP 2016519629A JP 2016519629 A JP2016519629 A JP 2016519629A JP 2016528180 A5 JP2016528180 A5 JP 2016528180A5
Authority
JP
Japan
Prior art keywords
compound
compound according
following structure
chr
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016519629A
Other languages
English (en)
Japanese (ja)
Other versions
JP6573604B2 (ja
JP2016528180A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/041997 external-priority patent/WO2014201172A1/en
Publication of JP2016528180A publication Critical patent/JP2016528180A/ja
Publication of JP2016528180A5 publication Critical patent/JP2016528180A5/ja
Application granted granted Critical
Publication of JP6573604B2 publication Critical patent/JP6573604B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016519629A 2013-06-11 2014-06-11 新規なglp−1レセプターモジュレーター Expired - Fee Related JP6573604B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361833737P 2013-06-11 2013-06-11
US61/833,737 2013-06-11
US201461981643P 2014-04-18 2014-04-18
US61/981,643 2014-04-18
PCT/US2014/041997 WO2014201172A1 (en) 2013-06-11 2014-06-11 Novel glp-1 receptor modulators

Publications (3)

Publication Number Publication Date
JP2016528180A JP2016528180A (ja) 2016-09-15
JP2016528180A5 true JP2016528180A5 (https=) 2017-07-06
JP6573604B2 JP6573604B2 (ja) 2019-09-11

Family

ID=51136825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016519629A Expired - Fee Related JP6573604B2 (ja) 2013-06-11 2014-06-11 新規なglp−1レセプターモジュレーター

Country Status (13)

Country Link
US (3) US9260427B2 (https=)
EP (1) EP3008056B8 (https=)
JP (1) JP6573604B2 (https=)
KR (1) KR102271179B1 (https=)
CN (2) CN109867630A (https=)
AU (1) AU2014278183B2 (https=)
BR (1) BR112015031040A8 (https=)
CA (1) CA2913791A1 (https=)
EA (1) EA030857B1 (https=)
ES (1) ES2864349T3 (https=)
HK (1) HK1222176A1 (https=)
MX (1) MX370666B (https=)
WO (1) WO2014201172A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規glp−1受容体安定剤および調節剤
BR112014013925B1 (pt) 2011-12-12 2022-02-22 Receptos Llc Compostos moduladores do receptor de glp-1 e composição e combinação farmacêutica compreendendo os ditos compostos
CN109867630A (zh) 2013-06-11 2019-06-11 赛尔基因第二国际有限公司 新型glp-1受体调节剂
CA2955836C (en) * 2014-07-25 2023-02-14 Celgene International Ii Sarl Glp-1 receptor modulators
ES2844573T3 (es) 2014-12-10 2021-07-22 Receptos Llc Moduladores del receptor de GLP-1
MX388576B (es) 2016-06-07 2025-03-20 Jacobio Pharmaceuticals Co Ltd Derivados heterociclicos novedosos utiles como inhibidores de shp2.
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
WO2018200833A1 (en) * 2017-04-28 2018-11-01 Celgene International Ii Sarl Novel glp-1 receptor modulators
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
CN109608524B (zh) * 2018-11-09 2022-06-03 北京志道生物科技有限公司 兼具dpp-4抑制及glp1r激活活性的多肽衍生物、制备和应用
HRP20241159T1 (hr) 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. Heterociklički agonisti za glp-1
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環glp—1促效劑
CN111548311B (zh) * 2020-06-04 2021-04-23 山西医科大学 一种小分子glp-1r激动剂及其应用
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト
JP2025509281A (ja) 2022-03-09 2025-04-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式glp-1アゴニスト
US20250206757A1 (en) 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN114989204A (zh) * 2022-06-16 2022-09-02 西北工业大学 一种葡萄糖响应自修复凝胶用的二苯乙炔类液晶态交联剂的制备方法
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1062206B (it) 1974-02-01 1983-09-20 Rotta Research Lab S P A A S Derivati della tirosina attivi sulla muscolatura liscia
DE2423536A1 (de) 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5780498A (en) * 1993-11-01 1998-07-14 Ciba-Geigy Japan Limited Endothelin receptor antagonists
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
DE122007000044I2 (de) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
PL338457A1 (en) 1997-07-31 2000-11-06 Elan Pharm Inc Sulphonylated dipeptidic compounds capable to inhibit adhesion of leucocytes through the mediation of vla-4
CN1276785A (zh) * 1997-08-22 2000-12-13 霍夫曼-拉罗奇有限公司 N-烷酰基苯丙氨酸衍生物
EP1005445B1 (en) * 1997-08-22 2004-05-26 F. Hoffmann-La Roche Ag N-alkanoylphenylalanine derivatives
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
JP4245682B2 (ja) * 1997-12-25 2009-03-25 協和発酵キリン株式会社 キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
EP1992641A3 (en) 1998-12-07 2009-07-29 Ipsen Pharma GLP-1 analogues
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
EP1150565A1 (en) * 1999-02-08 2001-11-07 LION bioscience AG Thiazole derivatives and combinatorial libraries thereof
JP3795305B2 (ja) * 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
DE60033684T2 (de) * 1999-11-18 2007-12-06 Ajinomoto Co., Inc. Phenylalaninderivate
CZ20022352A3 (cs) * 1999-12-06 2003-05-14 F. Hoffmann-La Roche Ag 4-pyridinyl-N-acyl-L-fenylalaniny
TR200401217T4 (tr) 2000-03-07 2004-06-21 Aventis Pharma Deutschland Gmbh İkameli 3-Fenil-5-Alkoksi-1,3,4-Oksdiazol-2-one (ve) hormona duyarlı lipazın önlenmesinde kullanılması
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
CA2420040C (en) * 2000-08-18 2009-02-03 Ajinomoto Co., Inc. New phenylalanine derivatives
WO2002028830A1 (en) * 2000-09-29 2002-04-11 Ajinomoto Co.,Inc. Novel phenylalanine derivatives
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
WO2003053926A1 (en) * 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Novel phenylalanine derivative
EP1477482B1 (en) 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Novel phenylalanine derivative
JPWO2003089410A1 (ja) * 2002-04-19 2005-08-25 協和醗酵工業株式会社 フェニルアラニン誘導体
US20070276034A1 (en) 2002-05-31 2007-11-29 Luke Esposito Compounds, compositions and methods for the treatment of synucleinopathies
PL224879B1 (pl) 2002-09-04 2017-02-28 Pharmacopeia Drug Discovery Inc Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja
MXPA05002571A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
US20040152750A1 (en) 2002-12-20 2004-08-05 Kodra Janos Tibor Novel glucagon antagonists
CN100436429C (zh) * 2003-02-20 2008-11-26 味之素株式会社 具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体
EP1644321B1 (en) 2003-06-13 2011-02-09 Laboratorios S.A.L.V.A.T., S.A. New benzamides as ppaty modulators
US7345049B2 (en) * 2003-12-22 2008-03-18 Ajinomoto Co., Inc. Phenylalanine derivatives
CA2555594A1 (en) * 2004-02-10 2005-08-25 Janssen Pharmaceutica N.V. Pyridazinones as antagonists of a4 integrins
JP4829506B2 (ja) * 2004-02-17 2011-12-07 石原産業株式会社 チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
WO2006117743A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Substituted aromatic compounds as antidiabetic agents
EP1899304A1 (en) 2005-05-23 2008-03-19 Arena Pharmaceuticals, Inc. 5-amino-1h-pyrazole-3-carboxylic acid derivatives as agonists for the g-protein coupled receptor (gpcr) rup38 for the treatment of metabolic-related disorders thereof
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
ES2416354T3 (es) * 2005-06-21 2013-07-31 Ajinomoto Co., Inc. Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo
JP2009516729A (ja) * 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ L−フェニルアラニン誘導体
JP2009539815A (ja) * 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のa5b1アンタゴニストとしてのN−(ベンゾイル)−O−[2−(ピリジン−2−イルアミノ)エチル]−L−チロシン誘導体と関連化合物
EP1878730A1 (en) 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
ES2380135T3 (es) * 2006-11-22 2012-05-08 Ajinomoto Co., Inc. Método de preparación de derivados de fenilalanina que tienen esqueleto de quinazolinadiona e intermedios para su preparación
WO2008064823A1 (en) * 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
US7816324B2 (en) 2007-03-13 2010-10-19 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by a peptide receptor
CA2688136A1 (en) 2007-06-08 2008-12-11 Advinus Therapeutics Private Limited Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
EP2205085A1 (en) * 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
ES2549768T3 (es) * 2010-03-29 2015-11-02 Ajinomoto Co., Inc. Cristal de sal hidrocloruro de derivado de fenilalanina
JP2013530963A (ja) 2010-06-09 2013-08-01 レセプトス インコーポレイテッド 新規のglp−1受容体安定化薬および調節薬
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規glp−1受容体安定剤および調節剤
US8999975B2 (en) * 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
BR112014013925B1 (pt) 2011-12-12 2022-02-22 Receptos Llc Compostos moduladores do receptor de glp-1 e composição e combinação farmacêutica compreendendo os ditos compostos
CN109867630A (zh) 2013-06-11 2019-06-11 赛尔基因第二国际有限公司 新型glp-1受体调节剂
CA2955836C (en) 2014-07-25 2023-02-14 Celgene International Ii Sarl Glp-1 receptor modulators

Similar Documents

Publication Publication Date Title
JP2016528180A5 (https=)
JP2014527027A5 (https=)
JP2017526734A5 (https=)
JP7418227B2 (ja) 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法
JP2017538711A5 (https=)
JP2015505842A5 (https=)
JP2019031560A5 (https=)
RU2014128522A (ru) Новые модуляторы рецептора glp-1
JP2018505898A5 (https=)
JP2016505619A5 (https=)
JP2013010793A5 (https=)
JP2018515495A5 (https=)
JP2018502891A5 (https=)
JP2013010792A5 (https=)
JP2016510323A5 (https=)
JP2013510883A5 (https=)
CA2679198A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2011500621A5 (https=)
MX389626B (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
ES2886571T3 (es) Inhibidores y sus usos
JP2010529969A5 (https=)
JP2024520656A (ja) Nash及びnafldを治療するための化合物
JP2017522304A5 (https=)
JP2016529235A5 (https=)
RU2016104844A (ru) Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора